Treatment of immunoglobulin A nephropathy with targeted-release budesonide (Kinpeygo ®▾ )

View at publisher Summarise with VIRAT
Authors: Richard Hull, Ayat Faggad, Lisa C. Willcocks
Cited by: 0
References: 18

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This article explores the evolving treatment of IgA nephropathy, highlighting targeted-release budesonide as the first licensed therapy to reduce proteinuria and slow disease progression when combined with optimised supportive care. This article was sponsored by Stada UK. Stada UK had no involvement in the creation of the content, which was independently developed by the authors Richard Hull, Ayat Faggad and Lisa Willcocks in partnership with MA Healthcare. Stada UK reviewed the article for technical accuracy and compliance only. Prescribing information and adverse event reporting can be found at the end of this article. UK-KINPE-215 | February 2026

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Journal of Kidney Care
Volume
11
Issue
2
Pages
60–66
Publication date
2 March 2026
Language
EN